| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 06/04/2009 | US20090142300 Compositions and methods related to toll-like receptor-3 |
| 06/04/2009 | US20090142280 Protective skin care peptides |
| 06/04/2009 | DE19549852B4 Cyclosporin enthaltende Präparate Cyclosporin-containing preparations |
| 06/04/2009 | CA2707107A1 Therapeutic targets and medicaments involving p230/golgin-245 |
| 06/04/2009 | CA2706656A1 Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition |
| 06/04/2009 | CA2706578A1 Amino triazoles as pi3k inhibitors |
| 06/04/2009 | CA2706429A1 Compositions for treating an intestinal inflammatory condition |
| 06/04/2009 | CA2706419A1 Antigen-binding constructs |
| 06/04/2009 | CA2706381A1 Processes for preparing a substituted gamma-amino acid |
| 06/04/2009 | CA2706333A1 Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the .beta.2 adrenergic receptor |
| 06/04/2009 | CA2705583A1 Derivatives of 6,7-dihydro-5h-imidazo[1,2-.alpha.]imidazole-3-carboxylic acid amides |
| 06/03/2009 | EP2065401A2 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 06/03/2009 | EP2065400A2 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 06/03/2009 | EP2065386A1 CGRP antagonists |
| 06/03/2009 | EP2065384A1 Tricyclic thrombin receptor antagonist |
| 06/03/2009 | EP2065382A1 CGRP antagonists |
| 06/03/2009 | EP2065381A1 CGRP antagonists |
| 06/03/2009 | EP2065366A2 HIF hydroxylase inhibitors |
| 06/03/2009 | EP2065053A1 Cell death inhibitor |
| 06/03/2009 | EP2065047A1 Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein |
| 06/03/2009 | EP2064227A2 Processes for the preparation of ciclesonide and its crystal form |
| 06/03/2009 | EP2064213A1 Heteroaryl derivatives as protein kinase inhibitors |
| 06/03/2009 | EP2064202A2 A new crystalline form g of (5s)-5-[4-(5-chloro-pyridin-2-yloxy)-piperidine-1-sulfonyl-methyl]-5-methyl-imidazolidine-2,4-dione (i) and intermediates thereof. |
| 06/03/2009 | EP2064194A2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| 06/03/2009 | EP1567145B1 Analgesic uses of (s)-norketamine |
| 06/03/2009 | EP1399472B1 Soluble heterodimeric cytokine receptor |
| 06/03/2009 | EP1399440B1 5-(2-aminopyrimidin-4-yl)benzisoxazoles as protein kinase inhibitors |
| 06/03/2009 | EP1313737B1 Novel guanidino derivatives as inhibitors of cell adhesion |
| 06/03/2009 | EP1218544B1 TAR RNA binding peptides |
| 06/03/2009 | CN101445504A Dioxane-2-alkyl carbamates derivatives |
| 06/03/2009 | CN101444509A Triple monoamine reuptake inhibitors for the treatment of chronic pain |
| 06/03/2009 | CN101444498A Use of retigabine or its medical salts for the treatment of neuropathic pain |
| 06/03/2009 | CN101444470A Use of oligosaccharides to stimulate beta-endorphin production |
| 06/03/2009 | CN100494182C Regulatory factor of tumor necrosis alpha factor |
| 06/03/2009 | CN100493617C Recombinant adeno-associated virus for prevention and cure of I-type diabetes and use thereof |
| 06/02/2009 | US7541376 3-(3-Fluoro-phenyl)-6-methoxy-1H-indazole-5-carboxylic acid(furan-2-ylmethyl)-amide; 3-Benzo[b]thiophen-2-yl-4-methoxy-1H-indazole-5-carboxylic acid[3-(2-oxo-pyrrolidin-1-yl)-propyl]-amide; Jun amino-terminal kinase (JNK) inhibitor; immunologic disease, inflammatory and neurodegenerative diseases |
| 06/02/2009 | US7541375 Azole derivatives and pharmaceutical compositions containing them |
| 06/02/2009 | US7541369 Amino-derivatives as novel inhibitors of histone deacetylase |
| 06/02/2009 | US7541368 Pyrazoles as inhibitors of tumor necrosis factor |
| 06/02/2009 | US7541362 7-(3,4-Dichlorophenyl)-4,7-dihydro-5-methyl-6-(5-phenyl-2-oxazolyl)pyrazolo[1, 5-a]pyrimidine |
| 06/02/2009 | US7541350 Formulation containing anti-inflammatory androstane derivative |
| 06/02/2009 | US7541031 Methods for treating rheumatoid arthritis using human antibodies that bind human TNFα |
| 06/02/2009 | US7541027 polyclonal antibodies, monoclonal antibodies, F(ab')2, Fab and single chain Fv; tyrosine at position 1214 in the amino acid sequence of the vascular endothelial growth factor receptor |
| 06/02/2009 | CA2434277C Substituted alkylamine derivatives and methods of use |
| 06/02/2009 | CA2395364C Model animal with onset of collagen-induced arthritis |
| 06/02/2009 | CA2349633C A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state |
| 06/02/2009 | CA2344290C Quinazoline derivatives |
| 06/02/2009 | CA2340416C Co-lyophilized complex of a nucleic acid vector and a formulating agent |
| 05/28/2009 | WO2009067703A2 Tapentadol compositions |
| 05/28/2009 | WO2009067618A1 Substituted benzoazole pde4 inhibitors for treating pulmonary and cardiovascular disorders |
| 05/28/2009 | WO2009067604A1 Substituted benzoazole pde4 inhibitors for treating inflammatory, cardiovascular and cns disorders |
| 05/28/2009 | WO2009067317A2 Use of levocabastine for modulating generation of pro- inflammatory cytokines |
| 05/28/2009 | WO2009067273A1 Pde5 inhibitors for treating pain caused by osteoarthritis |
| 05/28/2009 | WO2009067243A2 Modulation of cd40 expression |
| 05/28/2009 | WO2009066775A1 Amorphous form of heterocyclic compound, solid dispersion and medicinal preparation each comprising the same, and process for production of the same |
| 05/28/2009 | WO2009066457A1 External preparation composition comprising fatty acid-based ionic liquid as active ingredient |
| 05/28/2009 | WO2009065946A2 Pharmaceutical kit consisting of an oil-in-water emulsion and a solid composition |
| 05/28/2009 | WO2009065503A1 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents |
| 05/28/2009 | WO2009065395A2 Novel use of omega-3-fatty acid(s) |
| 05/28/2009 | WO2009049180A3 Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
| 05/28/2009 | WO2009026657A8 Flavonoid ppar agonists |
| 05/28/2009 | WO2009010968A3 Disease treatment via antimicrobial peptides or their inhibitors |
| 05/28/2009 | WO2008156638A3 Method of treating disorders that would benefit from increased levels of bilirubin in a subject |
| 05/28/2009 | US20090137845 Novel 4-Dedimethylaminotetracycline derivatives |
| 05/28/2009 | US20090137669 Creatine ester anti-inflammatory compounds and formulations |
| 05/28/2009 | US20090137656 Intermolecular Association Complex of a Carrier and of an Active Principle |
| 05/28/2009 | US20090137655 Non-Steroidal Ligands for the Glucocorticoid Receptor, Compositions and Uses Thereof |
| 05/28/2009 | US20090137647 Modified Macrophage Migration Inhibitory Factor Inhibitors |
| 05/28/2009 | US20090137625 Novel Enantiomers and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors |
| 05/28/2009 | US20090137604 corticotropin releasing factor receptor antagonists such as 8-(N-butyl-N-(2-butynyl)amino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine, used for the treatment of nervous system, psychological, eating, sleep, and gastrointestinal disorders |
| 05/28/2009 | US20090137588 Heteroaryl compounds and uses thereof |
| 05/28/2009 | US20090137583 2-aminoquinazoline derivatives |
| 05/28/2009 | US20090137575 Fused Tetracyclic mGluR1 Antagonists as Therapeutic Agents |
| 05/28/2009 | US20090137555 activity of CDK1, CDK2, CDK4, CDK5, GSK3 beta , Bcr-ab1, Flt-3, c-Kit, PDGFR beta , Src, Mek1 and CK1; 2-[N'-(2,3-dibromo-8-oxo-5,6,7,8-tetrahydro-1H-pyrrolo[2,3-c]azepin-4-ylidene)-hydrazino]-benzoic acid; antiinflammatory agent; autoimmune, neurological, cardiovasculal, hormone-related diseases |
| 05/28/2009 | US20090137513 RNA Interference Mediated Inhibition of Acetyl-CoA-Carboxylase Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| 05/28/2009 | US20090137512 nucleotide sequence complementary to a target RNA sequence and a second sequence chemically modified so it can no longer act as a guide sequence for mediating RNA interference, having complementarity to said first sequence; cancer, proliferative diseases |
| 05/28/2009 | US20090137511 RNA INTERFERENCE MEDIATED INHIBITION OF PLACENTAL GROWTH FACTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 05/28/2009 | US20090137509 RNA INTERFERENCE MEDIATED INHIBITION OF PROLIFERATION CELL NUCLEAR ANTIGEN (PCNA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 05/28/2009 | US20090137508 Treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability |
| 05/28/2009 | US20090137494 Tumor-activated prodrug compounds and treatment |
| 05/28/2009 | US20090137483 Antagonists of the bradykinin B1 receptor |
| 05/28/2009 | US20090137464 Therapeutic fibrin-derived peptides and uses thereof |
| 05/28/2009 | US20090137462 Pharmaceutical composition comprising cyclic somatostatin analogues |
| 05/28/2009 | US20090137452 Antagonists of the bradykinin B1 receptor |
| 05/28/2009 | US20090136497 Methods for inhibiting cutaneous inflammation and hyperpigmentation |
| 05/28/2009 | US20090136427 LIGHT Inhibitors For Asthma, Lung and Airway Inflammation, Respiratory, Interstitial, Pulmonary and Fibrotic Disease Treatment |
| 05/28/2009 | CA2722591A1 Substituted benzoazole pde4 inhibitors for treating pulmonary and cardiovascular disorders |
| 05/28/2009 | CA2722586A1 Substituted benzoazole pde4 inhibitors for treating inflammatory, cardiovascular and cns disorders |
| 05/28/2009 | CA2706596A1 Tapentadol compositions |
| 05/28/2009 | CA2706586A1 Novel compounds as cannabinoid receptor ligands and uses thereof |
| 05/28/2009 | CA2706536A1 Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same |
| 05/28/2009 | CA2705965A1 External preparation composition comprising fatty acid-based ionic liquid as active ingredient |
| 05/28/2009 | CA2705936A1 Use of omega-3-fatty acids for pain relief |
| 05/28/2009 | CA2705410A1 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents |
| 05/27/2009 | EP2062890A1 Tricyclic thrombin receptor antagonist |
| 05/27/2009 | EP2062884A1 Novel phenylacetic acid derivative |
| 05/27/2009 | EP2062880A1 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents |
| 05/27/2009 | EP2062879A1 Heterocyclic inhibitors of p38 |
| 05/27/2009 | EP2062595A1 Inhibition of inflammation using alpha 7 receptor-binding cholinergic agonists |
| 05/27/2009 | EP2062584A1 Adhesive preparation |